EP. 1: Introduction: Chemotherapies for Advanced Breast Cancer
EP. 2: Nab-Paclitaxel in Metastatic Breast Cancer
EP. 3: Exceptional Responders in Breast Cancer
EP. 4: First-Line Treatment of HER2-Positive MBC
EP. 5: HER2 Testing Challenges in Metastatic Breast Cancer
EP. 6: Upfront T-DM1 in HER2-Positive Breast Cancer
EP. 7: Utilizing pCR in Breast Cancer Trials
EP. 8: Fitting T-DM1 Into Established Upfront Treatment Paradigms
EP. 9: T-DM1 Plus Pertuzumab in the MARIANNE Trial
EP. 10: Frontline Treatment of ER-Positive Breast Cancer
EP. 11: Second-Line Everolimus in Metastatic Breast Cancer
EP. 12: Managing the Toxicity of Everolimus in Breast Cancer
EP. 13: Adjuvant Everolimus and CDK4/6 Trials in Breast Cancer
EP. 14: TEXT/SOFT Findings in HR-Positive Breast Cancer
EP. 15: Utilizing Bisphosphonates in Breast Cancer
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
